Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. (Q48253155)

10 February 2018

title

Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. (English)

1 reference

10 February 2018

16

Hagop Kantarjian

1 reference

10 February 2018

4

Srdan Verstovsek

1 reference

10 February 2018

3

Gautam Borthakur

1 reference

10 February 2018

7

Tapan Kadia

1 reference

10 February 2018

8

Farhad Ravandi

1 reference

10 February 2018

15

Elias Jabbour

1 reference

10 February 2018

13

Sherry Pierce

1 reference

PubMed ID

28972430

10 February 2018

Guillermo Garcia-Manero

5

Guillermo Garcia-Manero

1 reference

10 February 2018

17

Jorge Cortes

1 reference

10 February 2018

6

Naval Daver

1 reference

10 February 2018

Steven M Kornblau

12

Steven Kornblau

1 reference

10 February 2018

Sara Dellasala

14

Sara Dellasala

1 reference

10 February 2018

Ahmad Alhuraiji

10

Ahmad Alhuraiji

1 reference

10 February 2018

Jan A Burger

11

Jan Burger

1 reference

10 February 2018

author name string

Prajwal Boddu

1

1 reference

10 February 2018

Abdul Rashid Shah

2

1 reference

10 February 2018

Nitin Jain

9

1 reference

10 February 2018

publication date

3 October 2017

1 reference

10 February 2018

published in

Leukemia & Lymphoma

1 reference

10 February 2018

page(s)

1-11

1 reference

10 February 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

The choice of first-line chronic myelogenous leukemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Efficacy and safety of second-line ponatinib after failure of a single previous tyrosine kinase inhibitor for chronic myeloid leukemia patients in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Ponatinib in refractory Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

A review of the European LeukemiaNet recommendations for the management of CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Gene expression changes associated with progression and response in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Ponatinib in Philadelphia chromosome-positive leukemias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1379076

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28972430

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28972430

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1080/10428194.2017.1379076

1 reference

10 February 2018

0 references

1 reference

10 February 2018